UNSPSC 51182104: Felypressin

This classification denotes an antidiurectic hormone analogue with the molecular formula C46H65N13O11S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17N2918V6G, chemically known as vasopressin, 2-l-phenylalanine-8-l-lysine- but generally known as felypressin, which bears US NIH Compound Identifier 5956. European Medicines Agency schedules Felypressin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07529MIG.

UNSPSC 51182104 Felypressin is a Commodity code covering pharmaceutical active ingredients and finished formulations. State and local governments procure under this code as part of broader generic pharmaceuticals and over-the-counter product agreements that supply hospitals, clinics, correctional facilities, and other public health and human services operations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, solicits manufacturers and distributors of pharmaceutical products including felypressin and related vasopressor agents to serve member state and local facilities across multiple jurisdictions. Vendors must maintain current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, contractual relationships with authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., with established chargeback systems in place. Procurement emphasizes price competitiveness (weighted 75 percent in evaluation), EDI capability, and flexible pricing structures including flat price, net price formats, and WAC-minus pricing.

MMCAP's January 2026 RFP for Generic Multi Source Pharmaceuticals and Over the Counter Products (S1070000015802) represents the most recent state-local activity under this code. The solicitation, posted January 20, 2026 with a due date of March 26, 2026, targets multiple awards across participating states including Minnesota and Oregon, with contract terms effective July 1, 2026 through June 30, 2028. Awarded vendors must ensure product availability by May 15, 2026 and submit comprehensive product information including NDC codes, strength, dosage form, and packaging configurations through the ePro procurement system. Responses must include evidence of $5 million commercial general liability insurance, $2 million network security and privacy liability coverage, and $2 million professional liability coverage. The RFP does not identify specific set-aside designations, and contract award values are not disclosed in solicitation materials; however, all awarded vendors incur a 3 percent administrative fee on purchases with performance penalties ranging from $200 to $1,500 per violation.